ZBIO stock news
This page provides real-time market news, earnings updates, and company announcements related to Zenas BioPharma, Inc. (ZBIO).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-10 17:57 EST
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-02-20 21:18:06
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory
Finviz2026-02-28 15:57:50
Zenas BioPharma: An Evaluation of Fundamental Worth and Competitive Advantage from a Value Investor’s Perspective
101 finance2026-02-28 16:16:45
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-16 11:03:45
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-03-16 22:06:42
ENAVATE's Zenas Bio Pharma addition is just a side note — The main focus should be on the Obexelimab pipeline
101 finance2026-03-21 18:39:40
Zenas BioPharma CEO Invests $2.3M Amid Stock Drop—Does the Pipeline Hold More Value?
101 finance2026-03-21 18:43:01
Zenas BioPharma’s BLA filing planned for Q2 2026 is the key focus—other details are secondary.
101 finance2026-03-21 18:43:12
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Finviz2026-03-26 20:03:52
Zenas BioPharma Inc. recently announced that the proceeds from its financing will be specifically used to support the commercialization preparations of its core product, Obexelimab, in the US market.
老虎证券2026-03-26 20:06:25
Zenas BioPharma completes $300 million financing: issuance of convertible senior notes and common stock to accelerate autoimmune drug development Biopharmaceutical company Zenas BioPharma announced the completion of a concurrent public offering of 2.50% convertible senior notes due 2032 and common stock, raising a total of $300 million.
老虎证券2026-03-27 04:16:22
Zenas BioPharma’s Major Fundraising Drives MS Study Efforts—Yet Only Clinical Proof Can Lead the Way Forward
101 finance2026-04-01 00:36:50
Zenas BioPharma Jumps 10.8% After Hours—No Obvious Trigger Identified
101 finance2026-04-01 20:09:46
ZBIO Stalls as Analysts Split and Sector Fears Price Cuts
101 finance2026-04-10 01:00:49
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-03-16 22:06:42
ENAVATE's Zenas Bio Pharma addition is just a side note — The main focus should be on the Obexelimab pipeline
101 finance2026-03-21 18:39:40
Zenas BioPharma CEO Invests $2.3M Amid Stock Drop—Does the Pipeline Hold More Value?
101 finance2026-03-21 18:43:01
Zenas BioPharma’s BLA filing planned for Q2 2026 is the key focus—other details are secondary.
101 finance2026-03-21 18:43:12
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Finviz2026-03-26 20:03:52
Zenas BioPharma Inc. recently announced that the proceeds from its financing will be specifically used to support the commercialization preparations of its core product, Obexelimab, in the US market.
老虎证券2026-03-26 20:06:25
Zenas BioPharma completes $300 million financing: issuance of convertible senior notes and common stock to accelerate autoimmune drug development Biopharmaceutical company Zenas BioPharma announced the completion of a concurrent public offering of 2.50% convertible senior notes due 2032 and common stock, raising a total of $300 million.
老虎证券2026-03-27 04:16:22
Zenas BioPharma’s Major Fundraising Drives MS Study Efforts—Yet Only Clinical Proof Can Lead the Way Forward
101 finance2026-04-01 00:36:50
Zenas BioPharma Jumps 10.8% After Hours—No Obvious Trigger Identified
101 finance2026-04-01 20:09:46
ZBIO Stalls as Analysts Split and Sector Fears Price Cuts
101 finance2026-04-10 01:00:49
ZBIO stock chart
ZBIO stock detailsZBIO stock price change
On the last trading day, ZBIO stock closed at 20.86 USD, with a price change of -7.21% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more